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Respiratory viruses are not a common cause of ventilator-associated pneumonia (VAP).
Herpesviridae [Herpes simplex virus (HSV) and cytomegalovirus (CMV)] are detected fre-
quently in the lower respiratory tract of ventilated patients. HSV is detected between days
7 and 14 of invasive mechanical ventilation (IMV); presence of the virus does not neces-
sarily imply pathogenicity, but the association with adverse clinical outcomes supports the
hypothesis of a pathogenic role in a variable percentage of patients. Bronchopneumonitis
associated with HSV should be considered in patients with prolonged IMV, reactivation
with herpetic mucocutaneous lesions and those belonging to a risk population with burn
injuries or acute lung injury. Reactivation of CMV is common in critically ill patients and
usually occurs between days 14 and 21 in patients with deﬁned risk factors. The potential
pathogenic role of CMV seems clear in patients with acute lung injury and persistent res-
piratory failure in whom there is no isolation of bacterial agent as a cause of VAP.The best
diagnostic test is not deﬁned although lung biopsies should be considered in addition to
the usual methods before starting speciﬁc treatment. The role of mimivirus is uncertain
and is yet to be deﬁned, but the serologic evidence of this new virus in the context of VAP
appears to be associated with adverse clinical outcomes.
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INTRODUCTION
Nosocomial pneumonia is the most commonly acquired infec-
tion in intensive care units (ICUs). Its Frequency is 10 cases/1000
admissions approximately, however, it may increase to 20 times
that number in patients undergoing invasive mechanical ventila-
tion (IMV; Celis et al., 1988; Torres et al., 1990; American Thoracic
Society Documents, 2005). The overall incidence of ventilator-
associated pneumonia (VAP) may range between 15 and 20%
(Celis et al., 1988; Torres et al., 1990; Luna et al., 2003; Warren
et al., 2003; Koulenti et al., 2009). This complication prolongs the
length of hospital stay, increases healthcare costs and may increase
mortality (Fagon et al., 1993; Kollef, 1993; Warren et al., 2003;
Koulenti et al., 2009).
Classically, the etiology of this entity has been assumed to be
bacterial, although in a signiﬁcant percentage of patients with
clinical suspected VAP, no bacteria can be identiﬁed.
In recent years, the introduction of highly sensitive techniques
for detecting viruses in the respiratory tract, such as nucleic acid
ampliﬁcation by polymerase chain reaction (PCR), has signiﬁ-
cantly improved the diagnostic yield of infections such as com-
munity acquired pneumonia (CAP), increasing the isolation rate
from less than 10% (using traditional techniques) to 35% when
using PCR in CAP that requires hospital admission (Marcos et al.,
2009).
Recently, new evidence has shown that viral isolation in the res-
piratory tract of immunocompetent patients undergoing IMV is
higher than previously thought (Bruynseels et al., 2003; Ong et al.,
2004; Luyt et al., 2007). However, there are several limitations
regarding determining the role of viruses in VAP:
– Difﬁculty in establishing a causal relationship between the viral
isolate in the respiratory tract and pneumonia.
– Lack of an accessible gold standard for establishing the diagno-
sis.
– Lack of evidence regarding the efﬁcacy of antiviral therapy in
the context of suspected viral pneumonia during mechanical
ventilation.
INCIDENCE
In critically ill immunocompetent patients undergoing IMV, two
kind of virus may cause viral nosocomial pneumonia: Herpesviri-
dae or the“classic” respiratory viruses (inﬂuenza A, parainﬂuenza,
respiratory syncytial virus, rhinovirus, metapneumovirus, and
adenovirus).
Although many clinical studies are focused on a particular
aspect of the role of viruses in the critically ill patient, some
studies have determined the frequency of viral respiratory tract
involvement in patients with risk factors or suspected VAP.
Ideally, a study to address this issue should have an appropri-
ate design (prospective cohort) and should systematically evaluate
samples from the upper and lower respiratory tract and should
include nucleic acid ampliﬁcation (PCR). After an exhaustive
review of the literature, only three studies meet most of these
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FIGURE 1 | Pooled analysis of studies that have evaluated
the viral infection rate in the respiratory tract with more
than one diagnostic method, including PCR and/or culture
of virus in respiratory samples. *Two hundred one patients
were evaluated with pharyngeal swab and BAL (Luyt et al., 2007).
HSV-1, herpes simplex virus type 1; CMV, cytomegalovirus;
RSV, respiratory syncytial virus; BAL, bronchoalveolar lavage; BAS,
bronchoaspirate.
requirements (Bruynseels et al., 2003; Daubin et al., 2005; Luyt
et al., 2007). Figure 1 shows a pool analysis of these studies.
Although the presence of viruses in respiratory samples was
not always accompanied by a deﬁnitive diagnosis of viral VAP and
considering that not all the studies reported this ﬁnal diagnosis, all
of them reported a very low incidence of the “classic” respiratory
viruses. Herpes simplex virus (HSV) and cytomegalovirus (CMV)
were the most frequently isolated agents. For this reason, we will
focus on the description of the most relevant aspects regarding
respiratory infections associated with these viruses.
It should be clariﬁed, that because viral pneumonia due to
HSV and CMV during mechanical ventilation in the majority of
cases is assumed to be a reactivation from a previous infection
acquired outside the hospital, the term VAP, which implies noso-
comial acquisition of the infection, will not be used, instead we
will refer as viral reactivated pneumonia.
HERPES SIMPLEX VIRUS
Initial infection with the HSV usually occurs during childhood
and is asymptomatic in most cases. A small percentage of patients
may present with gingivostomatitis or pharyngitis.
Herpes simplex virus type 1 (HSV-1) may be isolated in the
saliva of between 1 and 5% of the healthy population. Several
factors such as tissue trauma, radiation therapy, heat exposure,
and acute bacterial infections may cause reactivation of the infec-
tion from a latent state, causing lesions of the skin and mucosa
(Simoons-Smit et al., 2006).
Lower respiratory tract infection with HSV-1 was initially con-
sidered as an entity exclusive of immunocompromised patients;
however, in the past two decades different studies have indicated
the potential role of HSV-1 in non-immunosuppressed patients
who are critically ill.
INCIDENCE AND RISK FACTORS
Herpes simplex virus respiratory infection in non-
immunosuppressed critically ill patients was ﬁrst reported in
patients with ARDS in 1983 (Tuxen et al., 1982). The presence
of HSV in the lower respiratory tract was previously thought to
be exceptional. Four studies evaluated necropsy series of unse-
lected patients between 1966 and 1982 and reported an incidence
of 42 cases per 8535 patients (0.5%) with a very high mortality
and mainly affecting patients with underlying malignancies and
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extensive burns (Tuxen, 1994). It was therefore assumed that respi-
ratory tract involvement of HSV was very unusual and associated
with a poor prognosis.
Findings of a high incidence of HSV in patients with
ARDS sparked interest in the hypothesis that HSV reactiva-
tion may play a role in an unfavorable clinical outcome in
non-immunosuppressed critically ill patients. This was reﬂected
in the increased number of publications reporting the frequency
of HSV.
The overall incidence reported thereafter ranged between 5
and 64% (Tuxen et al., 1982; Prellner et al., 1992; Schuller et al.,
1993; Byers et al., 1996; Cook et al., 1998, 2003; Cherr et al., 2000;
Bruynseels et al., 2003; Ong et al., 2004; Linssen et al., 2008; De
Vos et al., 2009). The wide variability of the reported incidence of
HSVwas due to differences in study designs, study population, and
the different use of diagnostic tests. Despite these differences, an
especially susceptible population, and different risk factors such as
extensive burns, ARDS, intubation, and prolonged IMV, positive
serology for HSV-1 (IgG), appearance of herpetic mucocutaneous
lesions, advanced age, high severity scores at admission, and use
of systemic corticoid therapy during the ICU stay were identiﬁed.
It should be noted that, despite the widely varying inci-
dence reported in the literature, the best quality study (in terms
of design, adequate number of studied patients, use of highly
sensitivity diagnostic tests, and consecutive evaluation of non-
immunosuppressed critically ill patients) showed a high incidence
of HSV detection in the lower respiratory tract (64%) and HSV
bronchopneumonitis (21%) among patients undergoing mechan-
ical ventilation for more than 5 days (Luyt et al., 2007). In this
study the presence of herpetic oral–labial lesions, positive pharyn-
geal swab, and macroscopic bronchial lesions were predictors for
herpetic bronchopneumonitis.
Table 1 shows a detailed summary of studies evaluating lower
respiratory tract infection caused by HSV-1 in critically ill patients
since 1982.
PATHOGENESIS
Reactivation of the latent virus seems to be the initial mechanism
of HSV respiratory infection: all patients with herpetic respiratory
infection in the ICU have a previous HSV-positive serology and,
usually, a pharyngeal swab positive for HSV, or oral–labial lesions
preceding the lower tract infection (Bruynseels et al., 2003; DeVos
et al., 2009).
Manipulation and traumatism of the airways predispose
patients to viral reactivation in the oropharyngeal mucosa and
upper airway, with subsequent micro-aspiration to further distal
airways, thereby causing potential lung parenchyma involvement
(Bruynseels et al., 2003; Simoons-Smit et al., 2006). Therefore,
viral reactivation on the tracheobronchial mucosa explains why,
in some cases, respiratory infection presents without any evidence
of viruses in the oropharyngeal mucosa (Tuxen, 1994; Luyt et al.,
2007).
Although hematogenous spread has been described, this mech-
anism seems to be limited to patients with a major degree of
immunosuppression (Ramsey et al., 1982).
Typically, viral reactivation begins between day 3 and 5 of
mechanical ventilation. This is followed by an exponential increase
of the viral load in the inferior airways, which reaches a peak on
day 12. Viral load at this point can reach up to 108 copies/mL as
measured by PCR performed on tracheobronchial secretions (De
Vos et al., 2009). This viral load corresponds to the viral concen-
tration found in the vesicular lesions of the oral mucosa. This
phase is followed by a slow decline of the viral load (Figure 2).
This chronology appears relevant when considering the diagnosis
of viral reactivated pneumonia on an individual basis.
It should be noted that a high viral load (assessed by viral
culture) appears to correlate well with the diagnosis of bron-
chopneumonitis based on histologic examination (cytology of
the bronchoalveolar lavage ﬂuid and/or bronchial biopsies are
assumed as the gold standard). A viral load of 8× 104 copies/106
cells has a sensitivity and a speciﬁcity of 81 and 83% respectively
for the diagnosis of herpetic bronchopneumonitis (Luyt et al.,
2007).
In animal models, the instillation of HSV into the nostrils
causes pneumonia and triggers a strong inﬂammatory response
with extensive tissuedamage secondary to inductionof nitric oxide
synthetase inducible enzyme on the lung parenchyma. Inhibition
of this enzyme improves tissue damage, pulmonary compliance,
and survival. Interestingly, these effects are independent of the
viral load, suggesting a mechanism of inﬂammatory response
ampliﬁcation rather than direct viral pathogenicity (Adler et al.,
1997).
It should be noted that although viral reactivation is the main
mechanism of pathogenesis of HSV pneumonia during mechan-
ical ventilation, there has been reported several cases of HSV
clusters due to nosocomial transmission in the ICU (Engelmann
et al., 2007).
CLINICAL OUTCOMES
The detection of HSV in the lower respiratory tract does not neces-
sarily mean lung infection and, on an individual basis, it is unclear
whether it represents viral contamination of the lower respira-
tory tract from the mouth and/or throat, local tracheobronchial
viral excretion or HSV bronchopneumonitis (Simoons-Smit et al.,
2006). For these reasons, the exact role of HSV remains to be clar-
iﬁed: is it just a marker of disease severity or a real pathogen with
its own morbidity and mortality?
The analysis is even more complicated when the association
of virus and bacteria in “viral” VAP (52% of cases) is taken into
consideration (Bruynseels et al., 2003; Luyt et al., 2007).
Several studies have found a higher number of days onmechan-
ical ventilation and longer stays in the ICU and/or hospital in
patients infected with HSV (Tuxen et al., 1982; Bruynseels et al.,
2003; Daubin et al., 2005; De Vos et al., 2009). Interestingly, these
were prospective studies that evaluated a large number of patients
and failed to show an increase in mortality.
The only prospective study that is often cited as an example
of increased mortality in the group of HSV + patients did not
reach statistical signiﬁcance when adjusted for severity, assessed
by APACHE II, which indicates that the results did not appear to
be consistent (Ong et al., 2004).
The studies that found increased mortality on infected patients
with HSV were retrospective (Cook et al., 1998; Bruynseels et al.,
2003) or prospective with a very small sample size and limited to
populations with ARDS (Tuxen et al., 1982).
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FIGURE 2 | Kinetics of HSV reactivation in patients undergoing IMV
evaluated with PCR on bronchoaspirate specime.
In consequence, the question of the effects of infection on
mortality remains to be clariﬁed.
TREATMENT
Despite the high incidence and association with adverse clini-
cal outcomes, there are no randomized control trials that make
possible to provide deﬁnitive recommendations regarding inter-
vention in these patients.
In all the studies mentioned, treatment was prescribed by the
clinicians and analysis of clinical outcomes under uncontrolled
conditions are not available. The only intervention study was a
small randomized trial that evaluated the efﬁcacy and safety of acy-
clovir for preventing reactivation of HSV in patients with ARDS
(Tuxen et al., 1987).
Although acyclovir was effective in preventing viral reactivation
in the respiratory tract (absolute risk reduction of 65%), there
was no difference in severity of respiratory failure, duration of
mechanical ventilations, and mortality between the control and
intervention arms.
Given the particular characteristics of this phenomenon (high
incidence, association with unfavorable clinical outcomes, and
potential therapeutic interventions), the need for randomized
clinical trials that might clarify this matter is imperative.
CYTOMEGALOVIRUS
Most healthy immunocompetent adults have been infected with
CMV, a fact that is evidenced by the presence of speciﬁc
immunoglobulin (Ig) G for this virus (Limaye et al., 2008). In
most cases, the infection remains latent without causing disease.
Reactivation and CMV disease has traditionally been described in
populations with marked alterations in cellular immunity (Ander-
son, 1991). However, in the past two decades there has been
increasing evidence to show that reactivation of CMV is a common
ﬁnding in the immunocompetent critically ill patients (Kalil and
Florescu, 2009). The frequency varies, according to the diagnostic
methods used, from 12% when cultures are used to 33% when
PCR is used (Limaye et al., 2008).
Viral reactivation begins between days 14 and 21 of the ICU
stay. Risk factors for reactivation are prolonged ICU stays, higher
severity scores on admission, and severe sepsis. In this group
the incidence may reach up to 36%. Although a clear cause and
effect has not been found, reactivation is associated with increased
mortality and longer hospital stay (Limaye et al., 2008; Kalil and
Florescu, 2009).
Viral reactivation in humans can begin in the lung parenchyma
(Papazian et al., 1996; Cook et al., 1998, 2003). In animal models
with latent CMV, sepsis may produce pulmonary reactivation of
the viral infection; this reactivation is associated with a persistent
increase of cytokine-mediated inﬂammatory response in the lung
and both ﬁndings (reactivation and persistent inﬂammation) do
not occur in the presence of prior ganciclovir treatment (Cook
et al., 2006).
Thus, to the epidemiological evidence of the association
of CMV-unfavorable clinical outcomes is added the biological
evidence of potential pathogenicity in the lungs.
In 1996, Papazian et al. (1996) published the ﬁrst study that
showed a high incidence of CMV reactivated pneumonia dur-
ing mechanical ventilation. The authors studied 85 patients with
ARDS, prolonged mechanical ventilation and suspected VAP
with negative cultures for bacteria in respiratory specimens (25
open lung biopsies and 60 post mortem biopsies). Conclusive
histopathological ﬁndings of CMV pneumonia were found in
25 patients (only three cases also showed evidence of bacterial
pneumonia).
The same authors studied the diagnostic value of open lung
biopsies on patients with acute lung injury, suspected VAP and
negative cultures of respiratory specimens, evaluating their utility
for potential changes to therapeutic interventions. In a sample of
100 patients, evidence of CMV infection was found in 30 subjects
(three patients hadHSVﬁndings), four cases also showed evidence
of ARDS in a ﬁbroproliferative phase. Together with the diagnosis
of pulmonary ﬁbrosis, CMV pneumonia was the most frequent
ﬁnding that conditioned changes in medical treatment (Papazian
et al., 2007).
The value of the different diagnostic techniques is not clear;
thus, in the ﬁrst study mentioned, the BAL culture had a sensitiv-
ity and a speciﬁcity of 53 and 92% respectively (Papazian et al.,
1996). In another study by the same authors, diagnosis was made
based onhistopathologic ﬁndings after negative cultures andnega-
tive pp. 65 antigenemia (Papazian et al., 2007). The only study that
evaluated PCR assay in BAL in an unselected sample of patients
with suspected VAP found 13% of positive samples without cyto-
plasmic inclusions and no histological evaluation was performed;
it was therefore not possible to reach a deﬁnitive diagnosis (Luyt
et al., 2007).
Consequently, the diagnosis CMV pneumonia during mechan-
ical ventilation may be more common than thought, but there are
difﬁculties and issues that still need to be clariﬁed regarding the
appropriate diagnostic tests. The above studies suggest a low sen-
sitivity of standard diagnostic tests. However, in the populations
studied,CMVappears to have a clear pathogenic role, as evidenced
by the extensive presence of pneumonitis and of cytoplasmic
inclusions in biopsy specimens (Papazian et al., 1996, 2007).
Individual management of each patient, is further compli-
cated when considering the risk and beneﬁts of treatment with
ganciclovir, which has potential serious adverse effects.
For these reasons, randomized clinical trials are needed to
clarify the role of antiviral treatment in patients with CMV
reactivation.
Similarly, it is difﬁcult to make a ﬁnal recommendation regard-
ing the overall approach to individual patients with suspected
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CMV pneumonia during mechanical ventilation. It may be rec-
ommendable to suspect this entity in patients with the before
mentioned risk factors and persistent pulmonary inﬁltrates with
clinical deterioration and no evidence of bacterial infection. If
the patient also shows evidence of viral reactivation (preferably
assessed by PCR), initiation of antiviral therapy should be con-
sidered. Lung biopsy appears to play an important role in this
group of patients because it can demonstrate CMV pneumonia
even when respiratory specimens are negative.
MIMIVIRUS
Acanthamoeba polyphaga (mimivirus) is a double-stranded DNA
virus with the largest viral genome yet described (Raoult et al.,
2004). Although it was thought to be a potential causative agent
of pneumonia, it’s role in this entity has not been categorically
deﬁned.
Theﬁndingof thismicroorganismwasdescribed in 1992 as part
of a suspected outbreak of Legionella pneumonia. Initially catego-
rized as a bacteria, it was ﬁnally reclassiﬁed as a virus in 2003.
Subsequently, serological evidence of mimivirus was reported in
between 7 and 9% of patients with community acquired and
nosocomial pneumonia (La Scola et al., 2005; Berger et al., 2006).
The potential role of this virus has been questioned in a study
that evaluated cohorts with pneumonia using different serolo-
gies; results were negative in all cases. The nosocomial pneumonia
cohort included 71 samples of elderly patients from health care
centers; it is not known if any of them received IMV (Dare et al.,
2008).
However, only one study has systematically evaluated ven-
tilated patients with suspected VAP (Vincent et al., 2009). Of
300 patients with suspected VAP, 59 had positive serology for
mimivirus (19.6%), 64% of those had positive BAL for bac-
teria. A comparison of mimivirus-seropositive patients with a
seronegative group matched for age, diagnostic category, and
severity showed that the seropositive group experienced increase
duration of MV and ICU stay; no differences in mortality were
found. It should be noted that the overall effectiveness of match-
ing was of 95% and other relevant variables such as adequate
antibacterial therapy and the bacteremia rate were similar in both
groups.
Thus, although no deﬁnitive recommendations can be made
regarding the screening of this microbiological agent, there is
ongoing cumulative evidence of the potential role of this new
virus in VAP.
CONCLUSION
Respiratory viruses are not a common cause of VAP. Herpesviridae
(HSV and CMV) are detected frequently in the lower respira-
tory tract of ventilated patients. HSV is detected between days 7
and 14 of IMV; presence of the virus does not necessarily imply
pathogenicity, but the association with adverse clinical outcomes
supports the hypothesis of a pathogenic role in a variable per-
centage of patients. Bronchopneumonitis associated with HSV
should be considered in patients with prolonged IMV, reactiva-
tion with herpetic mucocutaneous lesions and those belonging to
a risk population with burn injuries or acute lung injury.
Reactivation of CMV is common in critically ill patients and
usually occurs between days 14 and 21 in patients with deﬁned
risk factors. The potential pathogenic role of CMV seems clear in
patients with acute lung injury and persistent respiratory failure in
whom there is no isolation of bacterial agent as a cause of VAP. The
best diagnostic test is not deﬁned although lung biopsies should
be considered in addition to the usual methods before starting
speciﬁc treatment.
Due to the lack of randomized clinical trials, it is not possible to
make a deﬁnitive recommendation regarding the antiviral treat-
ment for suspected HSV or CMV reactivation pneumonia during
mechanical ventilation. The decision to start antiviral treatment
should be made on an individual basis, taking into consideration
the risk factors mentioned above, a correct interpretation of diag-
nostic methods and the hole clinical picture of the patient. There
is an imperative need for randomized clinical trials to address this
aspect.
The role of mimivirus is uncertain and still needs to be deﬁned,
but the serologic evidence of this new virus in the context of VAP
appears to be associated with adverse clinical outcomes.
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